CLEO DIAGNOSTICS LTD - Announcements

1.65%

61.5¢

Market Cap $82.80M

Healthcare Medical Care

Cleo Diagnostics Limited is an ovarian cancer diagnostics company. Its principal... Cleo Diagnostics Limited is an ovarian cancer diagnostics company. Its principal activities involve the development and patent of a blood test for the detection of ovarian cancer. It focuses on bringing to market a blood test for the early diagnosis of ovarian cancer based on the novel CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is absent in non-malignant disease. It is advancing the availability of its blood test, under a modular execution strategy, which is designed to address all ovarian cancer detection markets with specific tests, including surgical triage, recurrence, high risk, and early-stage screening. Triage Test is a pre-surgical test to determine ovarian or adnexal mass for which surgical referral is required who have not yet been referred to an oncologist.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

COV	Quarterly activities and cashflow report	PRICE SENSITIVE	29/01/26	5.57MB	Share
COV	Ceasing to be a substantial holder		05/01/26	241.52KB	Share
COV	Chairman's End of Year Letter to Shareholders		29/12/25	471.47KB	Share
COV	Cleansing Notice		29/12/25	310.82KB	Share
COV	Notification regarding unquoted securities - COV		29/12/25	16.85KB	Share
COV	Application for quotation of securities - COV		29/12/25	15.45KB	Share
COV	Application for quotation of securities - COV		29/12/25	15.64KB	Share
COV	Proposed issue of securities - COV		18/12/25	18.43KB	Share
COV	CLEO Raises $5m to Support U.S. Market Launch	PRICE SENSITIVE	18/12/25	524.58KB	Share
COV	Trading Halt	PRICE SENSITIVE	17/12/25	417.88KB	Share
COV	Notice under Listing Rule 3.10A		28/11/25	294.6KB	Share
COV	Cleo Strengthens Cash Position with $1.7m R&D Tax Refund	PRICE SENSITIVE	26/11/25	480.3KB	Share
COV	Results of Annual General Meeting		24/11/25	428.7KB	Share
COV	CLEO Appoints First Key Opinion Leader to Support US Market	PRICE SENSITIVE	19/11/25	524.49KB	Share
COV	CLEO Significantly Expands Addressable Market	PRICE SENSITIVE	06/11/25	526.77KB	Share
COV	Quarterly activities and cashflow report	PRICE SENSITIVE	31/10/25	677.54KB	Share
COV	CLEO Successfully Completes Stage 1 MDSAP Audit	PRICE SENSITIVE	30/10/25	519.71KB	Share
COV	Letter to Shareholders		25/09/25	2.63MB	Share
COV	Notice of Annual General Meeting/Proxy Form		25/09/25	680.21KB	Share
COV	Application for quotation of securities - COV		19/09/25	14.17KB	Share
COV	Cleo Receives Positive FDA Feedback	PRICE SENSITIVE	15/09/25	423.76KB	Share
COV	Notice Required Under ASX Listing Rule 3.13.1		05/09/25	310.58KB	Share
COV	Appendix 4G and Corporate Governance Statement		26/08/25	437.28KB	Share
COV	Appendix 4E and 2025 Annual Report	PRICE SENSITIVE	26/08/25	1.22MB	Share
COV	COV Commences Health Economic Study-Support US Market Entry	PRICE SENSITIVE	18/08/25	440.71KB	Share
COV	Restricted securities to be released from escrow		15/08/25	328.83KB	Share
COV	Quarterly activities and cashflow report	PRICE SENSITIVE	21/07/25	740.81KB	Share
COV	CLEO Strengthens FDA Submission - Access to US Biobank	PRICE SENSITIVE	25/06/25	545.31KB	Share
COV	Investor Webinar		18/06/25	396.94KB	Share
COV	Corporate Presentation	PRICE SENSITIVE	12/06/25	2.56MB	Share
COV	Cleo Advances with Completion of Alpha Testing	PRICE SENSITIVE	12/05/25	526.49KB	Share
COV	CLEO to Fast Track Development of Ovarian Cancer Test	PRICE SENSITIVE	28/04/25	522.41KB	Share
COV	Notification regarding unquoted securities - COV		24/04/25	20.62KB	Share
COV	CLEO Receives A$845k Research and Development Tax Incentive	PRICE SENSITIVE	24/04/25	473.54KB	Share
COV	Quarterly activities and cashflow report	PRICE SENSITIVE	11/04/25	751.94KB	Share
COV	CLEO Delivers Commercial Development Milestone	PRICE SENSITIVE	18/03/25	511.71KB	Share
COV	Appendix 4D and Half Yearly Accounts	PRICE SENSITIVE	27/02/25	596.53KB	Share
COV	Clarification to ASX Price Query		17/02/25	461.92KB	Share
COV	Price Query Response	PRICE SENSITIVE	07/02/25	889.55KB	Share
COV	Quarterly activities and cashflow report	PRICE SENSITIVE	31/01/25	812.43KB	Share
COV	CLEO Further Expands Ovarian Cancer Trial with Siles Health	PRICE SENSITIVE	10/12/24	2.71MB	Share
COV	Results of Annual General Meeting		27/11/24	367.57KB	Share
COV	The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial	PRICE SENSITIVE	27/11/24	2.79MB	Share
COV	Quarterly activities and cashflow report	PRICE SENSITIVE	16/10/24	711.6KB	Share
COV	Letter to Shareholders		04/10/24	2.18MB	Share
COV	Notice of Annual General Meeting/Proxy Form		04/10/24	731.29KB	Share
COV	Notice Required Under ASX Listing Rule 3.13.1		23/09/24	310.63KB	Share
COV	Cleo Commences U.S. Clinical Trials	PRICE SENSITIVE	06/09/24	526.04KB	Share
COV	ASX Listing Rule 4.10.19		28/08/24	348.64KB	Share
COV	Appendix 4G and Corporate Governance Statement		27/08/24	445.04KB	Share
COV	Appendix 4E and 2024 Annual Report	PRICE SENSITIVE	27/08/24	6.18MB	Share
COV	Change of Registry Address		07/08/24	355.59KB	Share
COV	CLEO Selects U.S. Clinical Trial Sites	PRICE SENSITIVE	31/07/24	2.76MB	Share
COV	Quarterly activities and cashflow report	PRICE SENSITIVE	24/07/24	732.66KB	Share
COV	Cleo Commences US Regulatory Process with FDA	PRICE SENSITIVE	26/06/24	2.75MB	Share
COV	Application for quotation of securities - COV		24/06/24	14.19KB	Share
COV	Restricted securities to be released from escrow		14/06/24	329.6KB	Share
COV	COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark	PRICE SENSITIVE	29/05/24	2.8MB	Share
COV	Quarterly activities and cashflow report	PRICE SENSITIVE	29/04/24	4.39MB	Share
COV	COV Appoints CRO to Manage US Ovarian Cancer Clinical Trials	PRICE SENSITIVE	11/04/24	2.78MB	Share
COV	CLEO Appoints Partner to Commence U.S. Market Access Program	PRICE SENSITIVE	02/04/24	2.79MB	Share
COV	Peer-Review Supports CLEOs Ovarian Cancer Detection Tech	PRICE SENSITIVE	25/03/24	2.79MB	Share
COV	Appendix 4D and Half Yearly Accounts	PRICE SENSITIVE	29/02/24	747.87KB	Share
COV	Corporate Presentation February 2024		20/02/24	2.32MB	Share
COV	Cleo Completes Design Transfer	PRICE SENSITIVE	12/02/24	2.7MB	Share
COV	Quarterly activities and cashflow report	PRICE SENSITIVE	31/01/24	996.59KB	Share
COV	Results of Annual General Meeting		22/11/23	400.96KB	Share
COV	Application for quotation of securities - COV		06/11/23	28.3KB	Share
COV	Completion of First Triage Test Clinical Validation Study	PRICE SENSITIVE	06/11/23	2.96MB	Share
COV	Trading Halt	PRICE SENSITIVE	03/11/23	714.91KB	Share
COV	Pause in Trading	PRICE SENSITIVE	03/11/23	115.61KB	Share
COV	Quarterly activities and cashflow report	PRICE SENSITIVE	30/10/23	4.67MB	Share
COV	Restricted securities to be released from escrow		27/10/23	331.54KB	Share
COV	Application for quotation of securities - COV		13/10/23	30.46KB	Share
COV	Cleo Delivers Early Progress on Development Program	PRICE SENSITIVE	09/10/23	3.17MB	Share
COV	Restricted securities to be released from escrow		06/10/23	331.89KB	Share
COV	Letter to Shareholders		05/10/23	307.45KB	Share
COV	Notice of Annual General Meeting/Proxy Form		05/10/23	515.34KB	Share
COV	Cleo Enhances Board Capacity		02/10/23	2.68MB	Share
COV	Appendix 4G and Corporate Governance Statement		27/09/23	445.92KB	Share
COV	Annual Report to shareholders		27/09/23	1.54MB	Share
COV	Notice Required Under ASX Listing Rule 3.13.1		22/09/23	310.07KB	Share
COV	Change of Registry Address		21/09/23	321.78KB	Share
COV	Application for quotation of securities - COV		19/09/23	30.19KB	Share
COV	Restricted securities to be released from escrow		12/09/23	352.09KB	Share
COV	Letter from the CEO to Shareholders		01/09/23	2.74MB	Share
COV	Appendix 4E and Preliminary Financial Report	PRICE SENSITIVE	31/08/23	694.36KB	Share
COV	CLEO Granted U.S. Patent for Novel Ovarian Cancer Biomarker		22/08/23	435.58KB	Share
COV	Initial Directors Interest Notices x 5		21/08/23	244.88KB	Share
COV	Notice of initial substantial holders x 3		21/08/23	797.37KB	Share
COV	Pre-Quotation Notice		18/08/23	398.21KB	Share
COV	Distribution Schedule		18/08/23	51.75KB	Share
COV	Top 20 Holders		18/08/23	63.74KB	Share
COV	Securities Trading Policy		18/08/23	176.54KB	Share
COV	Employee Securities Incentive Plan		18/08/23	511.56KB	Share
COV	Interim Report 31 December 2022		18/08/23	741.87KB	Share
COV	Annual Report 30 June 2022		18/08/23	752.4KB	Share
COV	Constitution		18/08/23	451.66KB	Share
COV	Replacement Prospectus		18/08/23	3.29MB	Share
COV	Information Form and Checklist		18/08/23	343.81KB	Share

COV Quarterly activities and cashflow report
29/01/26	PRICE SENSITIVE	5.57MB	Share
COV Ceasing to be a substantial holder
05/01/26		241.52KB	Share
COV Chairman's End of Year Letter to Shareholders
29/12/25		471.47KB	Share
COV Cleansing Notice
29/12/25		310.82KB	Share
COV Notification regarding unquoted securities - COV
29/12/25		16.85KB	Share
COV Application for quotation of securities - COV
29/12/25		15.45KB	Share
COV Application for quotation of securities - COV
29/12/25		15.64KB	Share
COV Proposed issue of securities - COV
18/12/25		18.43KB	Share
COV CLEO Raises $5m to Support U.S. Market Launch
18/12/25	PRICE SENSITIVE	524.58KB	Share
COV Trading Halt
17/12/25	PRICE SENSITIVE	417.88KB	Share
COV Notice under Listing Rule 3.10A
28/11/25		294.6KB	Share
COV Cleo Strengthens Cash Position with $1.7m R&D Tax Refund
26/11/25	PRICE SENSITIVE	480.3KB	Share
COV Results of Annual General Meeting
24/11/25		428.7KB	Share
COV CLEO Appoints First Key Opinion Leader to Support US Market
19/11/25	PRICE SENSITIVE	524.49KB	Share
COV CLEO Significantly Expands Addressable Market
06/11/25	PRICE SENSITIVE	526.77KB	Share
COV Quarterly activities and cashflow report
31/10/25	PRICE SENSITIVE	677.54KB	Share
COV CLEO Successfully Completes Stage 1 MDSAP Audit
30/10/25	PRICE SENSITIVE	519.71KB	Share
COV Letter to Shareholders
25/09/25		2.63MB	Share
COV Notice of Annual General Meeting/Proxy Form
25/09/25		680.21KB	Share
COV Application for quotation of securities - COV
19/09/25		14.17KB	Share
COV Cleo Receives Positive FDA Feedback
15/09/25	PRICE SENSITIVE	423.76KB	Share
COV Notice Required Under ASX Listing Rule 3.13.1
05/09/25		310.58KB	Share
COV Appendix 4G and Corporate Governance Statement
26/08/25		437.28KB	Share
COV Appendix 4E and 2025 Annual Report
26/08/25	PRICE SENSITIVE	1.22MB	Share
COV COV Commences Health Economic Study-Support US Market Entry
18/08/25	PRICE SENSITIVE	440.71KB	Share
COV Restricted securities to be released from escrow
15/08/25		328.83KB	Share
COV Quarterly activities and cashflow report
21/07/25	PRICE SENSITIVE	740.81KB	Share
COV CLEO Strengthens FDA Submission - Access to US Biobank
25/06/25	PRICE SENSITIVE	545.31KB	Share
COV Investor Webinar
18/06/25		396.94KB	Share
COV Corporate Presentation
12/06/25	PRICE SENSITIVE	2.56MB	Share
COV Cleo Advances with Completion of Alpha Testing
12/05/25	PRICE SENSITIVE	526.49KB	Share
COV CLEO to Fast Track Development of Ovarian Cancer Test
28/04/25	PRICE SENSITIVE	522.41KB	Share
COV Notification regarding unquoted securities - COV
24/04/25		20.62KB	Share
COV CLEO Receives A$845k Research and Development Tax Incentive
24/04/25	PRICE SENSITIVE	473.54KB	Share
COV Quarterly activities and cashflow report
11/04/25	PRICE SENSITIVE	751.94KB	Share
COV CLEO Delivers Commercial Development Milestone
18/03/25	PRICE SENSITIVE	511.71KB	Share
COV Appendix 4D and Half Yearly Accounts
27/02/25	PRICE SENSITIVE	596.53KB	Share
COV Clarification to ASX Price Query
17/02/25		461.92KB	Share
COV Price Query Response
07/02/25	PRICE SENSITIVE	889.55KB	Share
COV Quarterly activities and cashflow report
31/01/25	PRICE SENSITIVE	812.43KB	Share
COV CLEO Further Expands Ovarian Cancer Trial with Siles Health
10/12/24	PRICE SENSITIVE	2.71MB	Share
COV Results of Annual General Meeting
27/11/24		367.57KB	Share
COV The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial
27/11/24	PRICE SENSITIVE	2.79MB	Share
COV Quarterly activities and cashflow report
16/10/24	PRICE SENSITIVE	711.6KB	Share
COV Letter to Shareholders
04/10/24		2.18MB	Share
COV Notice of Annual General Meeting/Proxy Form
04/10/24		731.29KB	Share
COV Notice Required Under ASX Listing Rule 3.13.1
23/09/24		310.63KB	Share
COV Cleo Commences U.S. Clinical Trials
06/09/24	PRICE SENSITIVE	526.04KB	Share
COV ASX Listing Rule 4.10.19
28/08/24		348.64KB	Share
COV Appendix 4G and Corporate Governance Statement
27/08/24		445.04KB	Share
COV Appendix 4E and 2024 Annual Report
27/08/24	PRICE SENSITIVE	6.18MB	Share
COV Change of Registry Address
07/08/24		355.59KB	Share
COV CLEO Selects U.S. Clinical Trial Sites
31/07/24	PRICE SENSITIVE	2.76MB	Share
COV Quarterly activities and cashflow report
24/07/24	PRICE SENSITIVE	732.66KB	Share
COV Cleo Commences US Regulatory Process with FDA
26/06/24	PRICE SENSITIVE	2.75MB	Share
COV Application for quotation of securities - COV
24/06/24		14.19KB	Share
COV Restricted securities to be released from escrow
14/06/24		329.6KB	Share
COV COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
29/05/24	PRICE SENSITIVE	2.8MB	Share
COV Quarterly activities and cashflow report
29/04/24	PRICE SENSITIVE	4.39MB	Share
COV COV Appoints CRO to Manage US Ovarian Cancer Clinical Trials
11/04/24	PRICE SENSITIVE	2.78MB	Share
COV CLEO Appoints Partner to Commence U.S. Market Access Program
02/04/24	PRICE SENSITIVE	2.79MB	Share
COV Peer-Review Supports CLEOs Ovarian Cancer Detection Tech
25/03/24	PRICE SENSITIVE	2.79MB	Share
COV Appendix 4D and Half Yearly Accounts
29/02/24	PRICE SENSITIVE	747.87KB	Share
COV Corporate Presentation February 2024
20/02/24		2.32MB	Share
COV Cleo Completes Design Transfer
12/02/24	PRICE SENSITIVE	2.7MB	Share
COV Quarterly activities and cashflow report
31/01/24	PRICE SENSITIVE	996.59KB	Share
COV Results of Annual General Meeting
22/11/23		400.96KB	Share
COV Application for quotation of securities - COV
06/11/23		28.3KB	Share
COV Completion of First Triage Test Clinical Validation Study
06/11/23	PRICE SENSITIVE	2.96MB	Share
COV Trading Halt
03/11/23	PRICE SENSITIVE	714.91KB	Share
COV Pause in Trading
03/11/23	PRICE SENSITIVE	115.61KB	Share
COV Quarterly activities and cashflow report
30/10/23	PRICE SENSITIVE	4.67MB	Share
COV Restricted securities to be released from escrow
27/10/23		331.54KB	Share
COV Application for quotation of securities - COV
13/10/23		30.46KB	Share
COV Cleo Delivers Early Progress on Development Program
09/10/23	PRICE SENSITIVE	3.17MB	Share
COV Restricted securities to be released from escrow
06/10/23		331.89KB	Share
COV Letter to Shareholders
05/10/23		307.45KB	Share
COV Notice of Annual General Meeting/Proxy Form
05/10/23		515.34KB	Share
COV Cleo Enhances Board Capacity
02/10/23		2.68MB	Share
COV Appendix 4G and Corporate Governance Statement
27/09/23		445.92KB	Share
COV Annual Report to shareholders
27/09/23		1.54MB	Share
COV Notice Required Under ASX Listing Rule 3.13.1
22/09/23		310.07KB	Share
COV Change of Registry Address
21/09/23		321.78KB	Share
COV Application for quotation of securities - COV
19/09/23		30.19KB	Share
COV Restricted securities to be released from escrow
12/09/23		352.09KB	Share
COV Letter from the CEO to Shareholders
01/09/23		2.74MB	Share
COV Appendix 4E and Preliminary Financial Report
31/08/23	PRICE SENSITIVE	694.36KB	Share
COV CLEO Granted U.S. Patent for Novel Ovarian Cancer Biomarker
22/08/23		435.58KB	Share
COV Initial Directors Interest Notices x 5
21/08/23		244.88KB	Share
COV Notice of initial substantial holders x 3
21/08/23		797.37KB	Share
COV Pre-Quotation Notice
18/08/23		398.21KB	Share
COV Distribution Schedule
18/08/23		51.75KB	Share
COV Top 20 Holders
18/08/23		63.74KB	Share
COV Securities Trading Policy
18/08/23		176.54KB	Share
COV Employee Securities Incentive Plan
18/08/23		511.56KB	Share
COV Interim Report 31 December 2022
18/08/23		741.87KB	Share
COV Annual Report 30 June 2022
18/08/23		752.4KB	Share
COV Constitution
18/08/23		451.66KB	Share
COV Replacement Prospectus
18/08/23		3.29MB	Share
COV Information Form and Checklist
18/08/23		343.81KB	Share

REFRESH

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 61.5¢		Change 0.010(1.65%)		Mkt cap ! $82.80M

Open	High	Low	Volume
60.5¢	62.5¢	59.5¢	106.7K

Buyers (Bids)

Vol.	Price($)
488	60.5¢

Sellers (Offers)

Price($)	Vol.
61.5¢	482

Last trade - 13.03pm 16/02/2026 (20 minute delay)

COV (ASX) Chart

CLEO DIAGNOSTICS LTD - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available